Journal
CANCER CYTOPATHOLOGY
Volume 129, Issue 5, Pages 341-346Publisher
WILEY
DOI: 10.1002/cncy.22367
Keywords
blood test; early detection; liquid biopsy; lung carcinoma
Ask authors/readers for more resources
Screening for lung cancer using low-dose computed tomography scanners is currently proposed, but lacks sensitivity and specificity. Combining this approach with a blood test, such as liquid biopsy, may improve detection rates. Studies have explored various blood components as potential biomarkers for early cancer development.
Screening for lung cancer has become a reality in certain countries, most notably the United States, but its implementation currently is under discussion and not established in many nations, including France. Screening for lung cancer currently is proposed using a low-dose computed tomography scanner. However, this approach lacks sensitivity and specificity, and could be improved when combined with a blood test (so-called liquid biopsy). Such tests attempt to detect biomarker (s) of early cancer development. Thus, numerous studies performed within the last few years have examined different blood components including circulating tumor cells and free DNA and other circulating elements such as microRNAs, exosomes, antibodies, and proteins. Recent studies have highlighted the value of seeking a signature for the methylation of circulating free DNA, which can be specific for certain solid tumors, including lung carcinoma. The current study describes some recent developments in the use of liquid biopsies for the detection of early-stage lung cancers, even those that are not yet visible using a low-dose computed tomography scanner. (c) 2020 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available